The importance of appropriate patient selection necessitates novel clinical trial design and biomarker-driven trials to allow delivery of the right drug to the right patient at the right time—personalized cancer medicine. The WIN Consortium promotes collaboration between critical stakeholders and offers diverse populations of cancer patients the opportunity to participate in clinical trials with new drugs and biologics that target their tumor.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kim, E. S. et al. The BATTLE Trial (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination): Personalizing therapy for lung cancer. Proceedings of American Association of Cancer Research (Late Breaking Abstracts-1) (2010).
Wistuba, I. I. et al. Methodological and practical challenges for personalized cancer therapies. Nat. Rev. Clin. Oncol. 8, 135–141 (2011).
Bang, Y. et al. Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 28 (18 Suppl.), a3 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr. Richard L. Schilsky declares he is a consultant for Foundation Medicine. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Mendelsohn, J., Tursz, T., Schilsky, R. et al. WIN Consortium—challenges and advances. Nat Rev Clin Oncol 8, 133–134 (2011). https://doi.org/10.1038/nrclinonc.2010.230
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.230
This article is cited by
-
Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma
Pathology & Oncology Research (2016)
-
Mouse hospital and co-clinical trial project—from bench to bedside
Nature Reviews Clinical Oncology (2015)
-
Predictive, personalized, preventive, participatory (P4) cancer medicine
Nature Reviews Clinical Oncology (2011)